Ditchcarbon
  • Contact
  1. Organizations
  2. Pharmaceutics International, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 2 months ago

Pharmaceutics International, Inc. Sustainability Profile

Company website

Pharmaceutics International, Inc. (PII), headquartered in the United States, is a leading player in the pharmaceutical contract development and manufacturing industry. Founded in 1997, the company has established a strong presence in key operational regions, including North America and Europe. PII specialises in the formulation and production of complex drug products, particularly in the areas of injectable and oral dosage forms. With a commitment to innovation, Pharmaceutics International offers unique services such as customised formulation development and comprehensive analytical testing. The company has achieved notable milestones, including successful partnerships with major pharmaceutical firms, which solidify its market position as a trusted provider in the industry. PII's dedication to quality and regulatory compliance sets it apart, making it a preferred choice for clients seeking reliable pharmaceutical solutions.

DitchCarbon Score

How does Pharmaceutics International, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

82

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Pharmaceutics International, Inc.'s score of 82 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.

90%

Let us know if this data was useful to you

Pharmaceutics International, Inc.'s reported carbon emissions

Inherited from Jabil Inc.

Pharmaceutics International, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Jabil Inc., which may influence its climate commitments and reporting practices. Pharmaceutics International, Inc. has not established any documented reduction targets or specific climate pledges. However, as part of its corporate family, it may align with the sustainability initiatives and targets set by Jabil Inc. This includes potential commitments to the Science Based Targets initiative (SBTi) and other climate-related frameworks, although specific details regarding these initiatives are not provided. As the company continues to develop its sustainability strategy, it is essential to monitor any future disclosures that may outline its carbon emissions and climate commitments more clearly.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2015201620172018201920202021202220232024
Scope 1
37,100,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
1,182,767,000
0,000,000,000
0,000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
Scope 3
51,478,000
00,000,000
00,000,000
00,000,000
-
-
-
0,000,000,000
0,000,000,000
0,000,000,000

How Carbon Intensive is Pharmaceutics International, Inc.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Pharmaceutics International, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Pharmaceutics International, Inc.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Pharmaceutics International, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Pharmaceutics International, Inc.'s Scope 3 Categories Breakdown

Pharmaceutics International, Inc.'s Scope 3 emissions, which decreased by 13% last year and increased significantly since 2015, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 86% of Scope 3 emissions.

Top Scope 3 Categories

2024
Purchased Goods and Services
86%
Upstream Transportation & Distribution
7%
Capital Goods
3%
Fuel and Energy Related Activities
2%
Employee Commuting
1%
Business Travel
<1%
Upstream Leased Assets
<1%
Waste Generated in Operations
<1%

Pharmaceutics International, Inc.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Pharmaceutics International, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Pharmaceutics International, Inc.'s Emissions with Industry Peers

Bioserv Corporation

US
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

Alcami

US
•
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Avara Pharmaceutical Services, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

CoreRx, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 11 days ago

Adare Pharma Solutions

US
•
Pharmaceutical Preparation Manufacturing
Updated 11 days ago

Catalent

US
•
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251030.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy